Please login to the form below

Not currently logged in
Email:
Password:

Sanofi Genzyme

This page shows the latest Sanofi Genzyme news and features for those working in and with pharma, biotech and healthcare.

AZ says dropping MedImmune will help ‘streamline’ its R&D

AZ says dropping MedImmune will help ‘streamline’ its R&D

Nevertheless, as MedImmune has operated as a semi-independent unit within AZ – in much the same way as Genentech within Roche and Sanofi’s Genzyme – the decision raises questions about how

Latest news

  • Sanofi extends growth spurt thanks to Genzyme, Dupixent Sanofi extends growth spurt thanks to Genzyme, Dupixent

    US approval of Cablivi adds to good news. Sanofi has put a long run of decline caused by patent losses in its rear view mirror, with rare disease unit Genzyme and ... There was positive news for Sanofi’s new play in rare blood disorders.

  • Havas Lynx Group scoops nine Golds at PM Society Awards Havas Lynx Group scoops nine Golds at PM Society Awards

    Meanwhile, Sanofi Genzyme and Regeneron came out on top in the pharma category, collecting five Golds and one Silver. ... Target Award for Secondary Care Advertisement: Cognite for Tillots Pharma. Innovation: Havas Lynx for Sanofi Genzyme and Regeneron.

  • Dupixent helps put Sanofi back on growth track Dupixent helps put Sanofi back on growth track

    Gains for vaccine division Sanofi Pasteur and the company’s specialty medicines division, which along with Dupixent includes Genzyme’s rare disease drugs and multiple sclerosis therapies like Aubagio (teriflunomide), contributed ... Buoyed by an 8%

  • Sanofi gets EU OK for Ablynx flagship drug Cablivi Sanofi gets EU OK for Ablynx flagship drug Cablivi

    EMA clears the drug to treat adults with aTTP. Sanofi has EMA approval for its acquired thrombotic thrombocytopenic purpura (aTTP) therapy Cablivi, the main asset behind its 9.3bn acquisition of ... Sanofi reckons there are around 7, 500 patients with

  • Sanofi’s rare blood disorder drug Cablivi set for European approval Sanofi’s rare blood disorder drug Cablivi set for European approval

    Rare disease drug among notable CHMP recommendations. Sanofi is closing in on EU approval of Cablivi for acquired thrombotic thrombocytopenic purpura (aTTP) – the lead asset behind its 9.3bn acquisition of ... Europe looks set to be the first market

More from news
Approximately 16 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • Trust me, I’m from pharma Trust me, I’m from pharma

    Rather than assuming anything, Sanofi Genzyme took a step back and asked patients: how can we help? ... In Sanofi Genzyme’s case, it culminated in a set of briefs that were owned by the patients living with the disease.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Voyager Therapeutics/ Sanofi (Genzyme). Gene therapy - Parkinson's disease, Friedreich's ataxia and Huntington's disease.

  • Pharma deals during January 2014 Pharma deals during January 2014

    The other deal announced by Alnylam was the expansion of its deal with Sanofi (Genzyme unit_ to develop RNAi therapeutics in rare diseases. ... In 2008 Genzyme gained rights to ataluren from PTC Therapeutics at a cost of $100m.

  • Interview: Laure Thibaud, Sanofi Interview: Laure Thibaud, Sanofi

    overnight.” . The Genzyme deal, for which Thibaud was involved in the pre-acquisition stage of the agreement, as well as the company's subsequent integration into Sanofi, was particularly exciting, she ... Chris Viehbacher has said too that he was

  • Who tops the pharma list? Who tops the pharma list?

    The latter, an antiplatelet agent it co-marketed with Sanofi, enjoyed 2011 sales of $9.4bn - but, with Plavix accounting for more than a third of BMS revenues in 2010, the ... For example, Sanofi's 2011 acquisition of Genzyme gave it access to an

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest from PMHub

  • Lucid Group make the cut at the PMEAs 2017

    OptiMiSe: a Multichannel Learning Platform for Clinical Behaviour Change Among Multiple Sclerosis Specialist Nurses, by Sanofi Genzyme, with support from Lucid Group.

  • Create Health

    ConvaTec. DRG. Hill-Rom. Micrel. MSD. Rayner. Sanofi Genzyme. Smith &Nephew. Vagisil.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Fendix is the only NHS digital media network and it provides organisations, such as pharma, with unrivalled digital access to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics